Weekly Recap | Upstream Bio -0.72%, most brokers rate it buyWeekly Review·Oct 24, 2026 at 07:12 AMUPB-8.36%
Weekly Recap | Sellas Life Sciences +15.63%, consensus target well above spotWeekly Review·Oct 24, 2026 at 07:01 AMSLS+1.67%
Weekly Recap | Summit Therapeutics +5.74%, ivonescimab data stack upWeekly Review·Oct 24, 2026 at 07:00 AMSMMT-0.51%
Weekly Recap | Beigene +2.32%, Tevimbra combination survival data landsWeekly Review·Oct 24, 2026 at 06:49 AMONC-1.21%
Weekly Recap | Moderna -8.22%, sell-off after cancer vaccine dataWeekly Review·Oct 24, 2026 at 06:41 AMMRNA-1.25%MRNY-2.25%
Weekly Recap | Jasper Therapeutics +6.27%, consensus target above spotWeekly Review·Oct 24, 2026 at 06:41 AMJSPR+2.91%
Weekly Recap | Legend Biotech +4.27%, consensus target above spotWeekly Review·Oct 24, 2026 at 06:36 AMLEGN+1.96%
Weekly Recap | IOVA.US +3.45%, outperforming the S&P 500Weekly Review·Oct 24, 2026 at 06:31 AMIOVA-0.35%
Weekly Recap | Cybin -3.41%, consensus target above spotWeekly Review·Oct 24, 2026 at 06:23 AMHELP-2.95%
Weekly Recap | Capricor Therap -11.62%, consensus target above spotWeekly Review·Oct 24, 2026 at 06:03 AMCAPR-3.26%
Weekly Recap | Absci +11.27%, consensus target above spotWeekly Review·Oct 24, 2026 at 05:50 AMABSI-2.03%
Weekly Recap | SPDR S&P Biotech +3.62%, outperforming the S&P 500Weekly Review·Oct 24, 2026 at 05:00 AMXBI-1.38%
Weekly Recap | PPH.US +0.46%, sector split on mixed newsWeekly Review·Oct 24, 2026 at 04:43 AMPPH-1.80%
